You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia

    SBC: Iveena Delivery Systems, Inc.            Topic: NEI

    Project Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Computational Infrastructure for Automated Force Field Development and Optimization

    SBC: ATTMOS Inc.            Topic: 400

    Project AbstractOur overarching goal is to provide reliable and efficient tools that can be used in structure based drug discovery (SBDD). One crucial component of SBDD is to predict the structure of a drug molecule that binds to a protein involved in a certain disease. This is usually achieved using computer tools and the process consists of two steps, namely hit identification and lead optimizat ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Neurosessments: Developing a quick, objective motor test to prompt cognitivetesting in primary care

    SBC: NEUROSESSMENTS LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in the United States, affecting one out of every nine older adults. However, Alzheimer’s disease and related dementias (AD/ADRD) can be difficult to diagnose, with physicians missing nearly half of all probable dementia cases. Rates of missed diagnosis are even higher among Black older adults. The majority of ph ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease

    SBC: Recombinant Technologies LLC            Topic: NIA

    Abstract Alzheimer’s disease is the most common cause of dementia and fourth most common cause of death. Amyloid-beta (Aβ) plays a crucial role in initiation and progression of Alzheimer’s disease (AD). Removal of circulating Aβ would shift the equilibrium in Aβ levels between brain and blood towards blood. This shift would deplete brain amyloid levels and improve memory. Three commercial m ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Modular Virtual Reality Therapeutic for Opioid and Stimulant Use Disorders

    SBC: INNATEVR LLC            Topic: NIDA

    PROJECT SUMMARY Opioid and/or Stimulant Use Disorders (OUD/StUD) are chronic, recurring conditions that if left untreated, pose a significant and ongoing public health and safety threat, with costs associated with OUD alone in the US exceeding one trillion dollars annually. Virtual Reality Cue Exposure (VRCE) employs safe and controlled repeated exposure to a variety of substance use cues and envi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Home Monitoring of Metabolic Disorders

    SBC: SEQUITUR HEALTH CORP            Topic: NICHD

    PROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. 3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection

    SBC: SINTX TECHNOLOGIES, INC.            Topic: NIAMS

    PROJECT SUMMARYSpinal fusion is the standard treatment for persistent neck and back pain, but the hardware used to stabilize the fusion can harbor or even promote bacteria that lead to persistent, difficult-to-treat infections that are costly and damaging to patient health. Among the available materials for spinal fusion, polyether-ether-ketone (PEEK) cages stand out due to their strength, biocomp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Engineering next generation supercharged CAR T-cells against solid tumors

    SBC: Cellinfinity Bio, Inc.            Topic: 102

    Project summary Adoptive cell therapy has revolutionized cancer treatment and has immense potential to cure a variety of cancer types. Multiple critical barriers exist for current CAR-T therapy particularly in solid tumor, including insufficient T cells trafficking to the cancer site, lack of effective cancer cell killing, severe toxicity, strong immunosuppression in the tumor microenvironment, an ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. New approach for immune modulation against T1D

    SBC: EVOQ THERAPEUTICS, INC.            Topic: 200

    PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is an autoimmune disease that affects 1 in 300 people by the age of 18 in the US. T1D is characterized by acute onset of hyperglycemia resulting from immune-mediated destruction of the insulin- producing β-cells in the pancreas. There is currently no cure for T1D and the disease requires constant management where the current standard of care/manageme ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy

    SBC: Pure Green Pharmaceuticals            Topic: 200

    PROJECT SUMMARY/ABSTRACT Painful diabetic peripheral neuropathy (pDPN) is a severe and debilitating nerve dysfunction prevalent in over 30 million US diabetic patients. It adversely affects patients by causing sensory pain in the lower limbs, muscular weakness, predisposition to falls, decreased quality of life, and significant patient morbidity as a result of foot ulcerations, amputations, and di ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government